Trials / Active Not Recruiting
Active Not RecruitingNCT05698017
Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early to Moderate Stage Multiple System Atrophy (MSA)
Phase 1 Open-Label Study for Treatment of Early to Moderate Stage Multiple System Atrophy Patients With the Investigational Allogeneic Cell Therapy Product, hOMSC300
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Cytora Ltd. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Purpose of this phase 1 study is to assess the safety of intrathecal administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from early to moderate stage Multiple System Atrophy (MSA)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | hOMSC300 | Human Oral Mucosa Stem Cells |
Timeline
- Start date
- 2022-11-07
- Primary completion
- 2026-02-19
- Completion
- 2026-02-19
- First posted
- 2023-01-26
- Last updated
- 2025-01-29
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT05698017. Inclusion in this directory is not an endorsement.